

# Clinical trials of glibenclamide

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
<b>glibenclamide vs c (add on MET)</b>			
<b>Hermann , 1991</b> n=NA follow-up: 6 months	metformin + glibenclamide versus metformin	patients with non-insulin-dependent diabetes mellitus	Parallel groups
<b>glibenclamide vs control (add on MET)</b>			
<b>Marre (ass) , 2002</b> n=NA follow-up: 16 weeks	metformin-glibenclamide 500 mg/2.5 mg or metformin-glibenclamide 500 mg/5 mg, titrated with the intention to achieve fasting plasma glucose (FPG) <or = 7 mmol/l versus metformin 500 mg,	patients with Type 2 diabetes mellitus inadequately controlled by metformin monotherapy	Parallel groups double-blind
<b>Tosi , 2003</b> n=NA follow-up: 6 months	metformin 400 to 2,400 mg/d + glibenclamide 2.5 to 15 mg/d versus metformin (500 to 3,000 mg/d),	-	Cross over double-blind
<b>glibenclamide vs rosiglitazone (add on MET)</b>			
<b>Garber , 2006</b> n=NA follow-up: 24 weeks	metformin-glibenclamide 500/2.5 mg tablets (initial daily dose 1000/5 mg) versus metformin 500 mg plus rosiglitazone 4 mg (initial daily dose 1000-2000 mg + 4 mg, depending on previous treatment)	patients with type 2 diabetes inadequately controlled on metformin monotherapy	double-blind

More details and results :

- antidiabetic drugs for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q81>
- insulin secretagogues for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q409>
- insulin secretagogues - sulfonylureas for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q483>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy at <http://www.trialresultscenter.org/go-Q512>

## References

### **Hermann, 1991:**

Hermann LS, Bitzn PO, Kjellstrm T, Lindgrde F, Scherstn B Comparative efficacy of metformin and glibenclamide in patients with non-insulin-dependent diabetes mellitus. *Diabete Metab* 1991;17:201-8 [[1936477](#)]

### **Marre (ass), 2002:**

Marre M, Howlett H, Lehert P, Allavoine T Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin. *Diabet Med* 2002;19:673-80 [[12147149](#)]

### **Tosi, 2003:**

Tosi F, Muggeo M, Brun E, Spiazzi G, Perobelli L, Zanolin E, Gori M, Coppini A, Moghetti P Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. *Metabolism* 2003;52:862-7 [[12870162](#)]

### **Garber, 2006:**

Garber A, Klein E, Bruce S, Sankoh S, Mohideen P Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. *Diabetes Obes Metab* 2006;8:156-63 [[16448519](#)] [10.1111/j.1463-1326.2005.00570.x](#)

Entry terms: glyburide, Glyburide, Glybenclamide, Glibenclamide, Diabeta, Euglucon 5, Neogluconin, HB-419, HB 419, HB419, HB-420, HB 420, HB420, Maninil, Micronase, Daonil, Euglucon N, , 4-transhydroxy glyburide, , Glucovance, Glyburide-metformin,